BofA warns Fed risks policy mistake with early rate cuts
Merit Medical Systems Inc. (NASDAQ:MMSI), a $6 billion medical device company with a GREAT financial health score according to InvestingPro, saw its CFO and Treasurer Raul Jr. recently execute significant transactions involving the company’s common stock. According to a recent SEC filing, Raul Jr. sold 5,361 shares on March 5, 2025, at a weighted average price of $103.58 per share. This sale amounted to a total value of approximately $555,292.
In addition to the sale, Raul Jr. also exercised non-qualified stock options, acquiring 5,361 shares at an exercise price of $37.71 per share, with a total transaction value of $202,163. Following these transactions, Raul Jr. holds 24,201 shares of Merit Medical Systems directly. The stock, which has delivered a 40% return over the past year, currently trades slightly above its InvestingPro Fair Value. Investors seeking deeper insights can access the comprehensive Pro Research Report, which includes detailed analysis of Merit Medical (TASE:BLWV)’s valuation metrics and growth prospects.
In other recent news, Merit Medical Systems Inc. reported its fourth-quarter 2024 earnings, showcasing a strong performance with earnings per share (EPS) of $0.93, surpassing the forecasted $0.82. The company’s revenue for the quarter reached $355.2 million, exceeding expectations and reflecting a 9% year-over-year increase. Analysts from Oppenheimer, Needham, and Raymond (NSE:RYMD) James have adjusted their price targets for Merit Medical to $116, with Raymond James raising it from $110, while Oppenheimer and Needham lowered theirs from $120 and $122, respectively. Despite these adjustments, both Oppenheimer and Raymond James maintained an Outperform rating, while Needham retained a Buy rating.
Merit Medical’s gross margin improved significantly by approximately 300 basis points year-over-year, marking its highest ever, according to Raymond James. The company’s free cash flow also saw a substantial increase of 67%, totaling $185 million for the full year 2024. Looking ahead, Merit Medical has provided guidance for 2025, projecting revenue growth between 8% and 10%, though EPS guidance fell slightly below consensus expectations due to an increase in share count from convertible securities. The company anticipates continued organic growth and margin expansion, supported by recent acquisitions such as Cook Medical and EndoGastric Solutions, which are performing better than initially expected.
Merit Medical’s WRAPSODY system is expected to contribute $7-9 million in revenue for 2025, with Needham analysts suggesting this projection may be conservative. The company’s organic revenue growth in the fourth quarter of 2024 was 6.1% year-over-year, an improvement from the previous quarter. Merit Medical’s strategic initiatives and strong operational foundation position it well for sustained growth and profitability, as highlighted by the analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.